Spectral Medical, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA8475771033
CAD
1.39
-0.03 (-2.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

36.83 k

Shareholding (Dec 2024)

FII

0.01%

Held by 1 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 0.81% and Operating profit at -8.36% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.33
2

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 411 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.24

stock-summary
Return on Equity

13.87%

stock-summary
Price to Book

-5.89

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.92%
0%
6.92%
6 Months
-2.8%
0%
-2.8%
1 Year
67.47%
0%
67.47%
2 Years
223.26%
0%
223.26%
3 Years
379.31%
0%
379.31%
4 Years
371.19%
0%
371.19%
5 Years
162.26%
0%
162.26%

Spectral Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
3.25%
EBIT Growth (5y)
-7.98%
EBIT to Interest (avg)
-8.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
-0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.45
EV to EBIT
-32.81
EV to EBITDA
-33.51
EV to Capital Employed
-7.19
EV to Sales
143.82
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -33.33% vs 50.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -187.50% vs 149.23% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.60",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-2.50",
          "chgp": "8.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "1.00",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "8.50",
          "chgp": "-97.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.80",
          "val2": "3.20",
          "chgp": "-187.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,204.20%",
          "val2": "-3,942.60%",
          "chgp": "-226.16%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 4.35% vs 43.75% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -209.74% vs 0.65% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.40",
          "val2": "2.30",
          "chgp": "4.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.40",
          "val2": "-11.70",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.20",
          "val2": "3.20",
          "chgp": "62.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-38.00",
          "val2": "2.50",
          "chgp": "-1,620.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.70",
          "val2": "-15.40",
          "chgp": "-209.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,785.00%",
          "val2": "-5,248.00%",
          "chgp": "46.30%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.40
0.60
-33.33%
Operating Profit (PBDIT) excl Other Income
-2.30
-2.50
8.00%
Interest
1.50
1.00
50.00%
Exceptional Items
0.20
8.50
-97.65%
Consolidate Net Profit
-2.80
3.20
-187.50%
Operating Profit Margin (Excl OI)
-6,204.20%
-3,942.60%
-226.16%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -33.33% vs 50.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -187.50% vs 149.23% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
2.40
2.30
4.35%
Operating Profit (PBDIT) excl Other Income
-11.40
-11.70
2.56%
Interest
5.20
3.20
62.50%
Exceptional Items
-38.00
2.50
-1,620.00%
Consolidate Net Profit
-47.70
-15.40
-209.74%
Operating Profit Margin (Excl OI)
-4,785.00%
-5,248.00%
46.30%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 4.35% vs 43.75% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -209.74% vs 0.65% in Dec 2024

stock-summaryCompany CV
About Spectral Medical, Inc. stock-summary
stock-summary
Spectral Medical, Inc.
Pharmaceuticals & Biotechnology
Spectral Medical Inc. is a late stage theranostic company advancing therapeutic options for sepsis and septic shock. The Company has developed a product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA). The EAA is a rapid in-vitro diagnostic test that measures negative bacterial cell wall (endotoxin) activity in a whole blood sample. The Company, through its wholly owned subsidiary, Dialco Medical Inc. (Dialco), is also commercializing a new platform, SAMI. Its platform is targeting the renal replacement therapy (RRT) market.
Company Coordinates stock-summary
Company Details
135 - 2 The West Mall , TORONTO ON : M9C 1C2
stock-summary
Tel: 1 416 62632331 416 9623300
stock-summary
Registrar Details